Development and improvement of anti-gout property from aqueous-methanol extract of morinda elliptica using central composite design

Xanthine oxidase (XO) is a key enzyme in hyperuricemia, catalyzing the oxidation of hypoxanthine to xanthine and then to uric acid. Excess serum accumulated with uric acid leads to a type of arthritis known as gout. In this study, development of process conditions for XO inhibitory activity from...

Full description

Saved in:
Bibliographic Details
Main Authors: Jamal, Parveen, Azmi, Saiful Mohammad Nizam, Amid, Azura, Mohd. Salleh, Hamzah, Hashim, Yumi Zuhanis Has-Yun
Format: Article
Language:English
English
Published: AENSI Publications 2014
Subjects:
Online Access:http://irep.iium.edu.my/36413/1/734-743_Parveen_.pdf
http://irep.iium.edu.my/36413/4/36413_Development%20and%20improvement%20of%20anti-gout_SCOPUS.pdf
http://irep.iium.edu.my/36413/
http://www.aensiweb.com/old/aeb/2014/734-743.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Xanthine oxidase (XO) is a key enzyme in hyperuricemia, catalyzing the oxidation of hypoxanthine to xanthine and then to uric acid. Excess serum accumulated with uric acid leads to a type of arthritis known as gout. In this study, development of process conditions for XO inhibitory activity from the leaves of Morinda elliptica was performed by using 70% methanol. Optimization of process parameters such as extraction temperature (ºC), extraction time (h), agitation speed (rpm) and ratio of sample to solvent (1g/ml) at five levels was carried out using central composite design (CCD) for the improvement of activity to treat gout. The analysis of variance demonstrated that the model F-value of 18.31 showed the significance of the model with R2 of 97.71%. The analysis revealed that the percentage of XO inhibitory activity was improved at 32 ºC, 30 h, 125 rpm and 1 g/15 ml of solvent. The optimized conditions were verified and the percentage of XO inhibitory activity obtained was 88.93%. The results are encouraging to formulate food, nutraceutical or pharmaceutical products incorporating natural xanthine oxidase inhibitor (XOI), an alternative to irresponsive synthetic XOI.